Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-102 in FGFR2b-overexpressing untreated advanced gastric or gastroesophageal junction adenocarcinoma
CTR20233946Phase 3Terminated
- Sponsor
- Amgen
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bemarituzumab, nivolumab, mFOLFOX6, Capecitabine + oxaliplatin in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Amgen. Started Mar 2024; status: terminated.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20233946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233946.